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ABSTRACT
Introduction Complications due to unsafe abortions are 
an important cause of morbidity and mortality in many 
sub- Saharan African countries. We aimed to characterise 
abortion- related complication severity, describe their 
management, and to report women’s experience of 
abortion care in Africa.
Methods A cross- sectional study was implemented 
in 210 health facilities across 11 sub- Saharan African 
countries. Data were collected on women’s characteristics, 
clinical information and women’s experience of abortion 
care (using the audio computer- assisted self- interviewing 
(ACASI) system). Severity of abortion complications 
were organised in five hierarchical mutually exclusive 
categories based on indicators present at assessment. 
Descriptive bivariate analysis was performed for 
women’s characteristics, management of complications 
and reported experiences of abortion care by severity. 
Generalised linear estimation models were used to assess 
the association between women’s characteristics and 
severity of complications.
Results There were 13 657 women who had an 
abortion- related complication: 323 (2.4%) women were 
classified with severe maternal outcomes, 957 (7.0%) 
had potentially life- threatening complications, 7953 
(58.2%) had moderate complications and 4424 (32.4%) 
women had mild complications. Women who were single, 
multiparous, presenting ≥13 weeks of gestational age and 
where expulsion of products of conception occurred prior 
to arrival to facility were more likely to experience severe 
complications. For management, the commonly used 
mechanical methods of uterine evacuation were manual 
vacuum aspiration (76.9%), followed by dilation and 
curettage (D&C) (20.1%). Most frequently used uterotonics 
were oxytocin (50∙9%) and misoprostol (22.7%). Via ACASI, 
602 (19.5%) women reported having an induced abortion. 
Of those, misoprostol was the most commonly reported 
method (54.3%).
Conclusion There is a critical need to increase access to 
and quality of evidence- based safe abortion, postabortion 
care and to improve understanding around women’s 
experiences of abortion care.
Key questions
What is already known?
 ► According to the most recent estimates, unsafe 
abortions account for half of all abortions globally, 
with the majority of the abortion- related deaths oc-
curring in Africa.
 ► As a result, serious complications arise from unsafe 
abortions; however, given the lack of use of standard 
definitions, identification criteria and standardised 
measurement tools, as well as variations in estima-
tions of the complications, there is limited evidence 
on the morbidity associated with abortion- related 
complications.
 ► As stated at the 1994 International Conference on 
Population and Development (ICPD) and reiterated in 
2019 at ICPD25, it is imperative to reduce abortion- 
related complications as it is an integral part of 
sexual and reproductive health and key to reducing 
maternal mortality.
What are the new findings?
 ► This is one of the few global studies to provide 
data on abortion- related complications, collecting 
data across 210 health facilities in 11 sub- Saharan 
African countries using a standardised tool.
 ► This study provides insights on the burden and man-
agement of abortion- related complications in health 
facilities using a hierarchal severity gradient, ac-
cording to sociodemographic, obstetric and clinical 
characteristics.
 ► Furthermore, this is the first WHO multicountry sur-
vey to explore women’s experience of care during 
postabortion care.
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INTRODUCTION
According to the most recent estimates, between 2015 
and 2019, 73.3 million abortions occurred worldwide 
each year, with 8 million abortions occurring in sub- 
Saharan Africa.1 2 Globally, it has been estimated that 
45.1% (95% CI 40.6 to 50.1) abortions are unsafe,1 2 
with75.6% (95% CI 66.4 to 81·4) of abortions occurring 
in the Africa region classified as unsafe. In the region, 
almost all unsafe abortions were categorised as least safe, 
the lowest ranking in the three- tiered approach, defined 
as abortion provision by untrained individuals using a 
dangerous method.1 The highest proportion of least safe 
abortions occurred in middle Africa, followed by West 
Africa and East Africa. To inform better policies and 
practices related to safe abortion and postabortion care, 
WHO has been developing guidelines on management 
of abortion, the role of healthcare workers including the 
women herself in the case of medical abortion as well as 
management of abortion- related complications.3–5 WHO 
has recently updated its recommendations, synthesising 
the latest evidence, to respond to the increased use of 
medical abortion globally.6
Severe abortion- related complications arise from least 
safe abortions with almost a third (31.3%, 95% CI 21.0 to 
41.9) in legally restrictive settings.1 These complications 
are an important and preventable cause of maternal 
mortality.7 Between 2008 and 2013, it was estimated that 
9.6% (95% CI 5.1 to 17.2) of maternal deaths are attrib-
utable to abortion- related causes in sub- Saharan Africa.7 
Studies that look at the morbidity from abortion globally 
and in Africa, using a standard measurement of severity 
and management of these complications are limited and 
varied.8–13 Current studies offer quantification of the 
abortion- related complications, but they often do not 
investigate the gradient or severity of these complications 
and, do not assess the quality of the care provided.
Since the initial launch and 25th anniversary of the 
International Conference on Population and Develop-
ment, it has been stated that abortion care is an integral 
part of sexual and reproductive health.14 15 However, the 
provision of safe abortion and postabortion care in many 
countries may be hindered by legally restrictive abortion 
laws and policies, weak health systems, socioeconomic 
conditions, the availability of safe abortion services and 
the stigma surrounding abortion. Capturing accurate 
information on abortion care can be challenging in such 
restricted settings. Furthermore, the Lancet Commission 
on High- Quality Health Systems highlighted that stig-
matised conditions such as abortion make individuals 
more susceptible and vulnerable to poor- quality care.16 
Women’s experiences of care should be an integral 
component of high- quality abortion care.17
Previous WHO multicountry survey research network 
studies on maternal and newborn health have been limited 
in terms of the insight they provided on abortion- related 
complications.18–20 To inform policy and programmatic 
actions to improve quality of abortion- related care in 
facilities, in the multicountry survey on abortion- related 
morbidity (MCS- A), we evaluated the severity of abortion- 
related complications and the management of these 
complications, and explored the experience of abortion 
care reported by women across 11 sub- Saharan African 
countries.21
METHODS
Study design and participants
The study protocol of the WHO MCS- A study has been 
published previously, describing the methodology of 
the cross- sectional study with prospective data collec-
tion across health facilities.21 This analysis focuses on the 
primary findings from the sub- Saharan Africa region. 
Briefly, after a multistage sampling, the 11 participating 
countries were identified (Benin, Burkina Faso, Chad, 
Democratic Republic of the Congo (DRC), Ghana, 
Kenya, Malawi, Mozambique, Niger, Nigeria, Uganda), 
followed by provinces and facilities in each country.22
Health facilities were only eligible if they fulfilled the 
following characteristics: >1000 deliveries per year, a 
gynaecology ward and surgical capability (defined as 
providing the signal functions for comprehensive emer-
gency obstetric care, which includes removal of retained 
products and surgical capability23 and, if available, abor-
tion provision and/or postabortion care. To ensure 
each facility could contribute sufficient data to the study 
during the 3- month data collection period, facilities 
reporting <10 postabortion care patients on average over 
a month in the facility assessment form were excluded. In 
each country, data collection took place over a 3- month 
period between February 2017 and April 2018.
All women presenting to the participating facilities with 
signs and symptoms or death at discharge from abortion- 
related complications or early pregnancy loss (including 
ectopic and molar pregnancies) were included. Pregnant 
women with a diagnosis of threatened abortion, defined 
as vaginal bleeding with a closed cervix were excluded.24 
The criterion of all women presenting to the facilities 
rather than admission to the facility was used to avoid 
exclusion of those women who seek care in the facilities 
for mild complications. Women with abortion- related 
complications who were admitted or had a prolonged 
hospital stay (>24 hours), able and were willing to 
consent were eligible to participate in the exit survey and 
convenience sampling was used to invite eligible women 
Key questions
What do the new findings imply?
 ► Abortion- related complications are an important underlying and 
contributing cause of maternal morbidity and mortality as unsafe 
abortion remains a critical public health issue in sub- Saharan Africa.
 ► Further efforts are required to increase access to safe abortion and 
contraception services and improving the quality of postabortion 
care including the implementation of evidence- based practices and 
better understanding around women’s experiences of abortion care.
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to participate in the exit survey based on the workload of 
data collectors and time of day in the study facility.
Procedures
A hospital administrator or a healthcare provider respon-
sible for the gynaecology and obstetrics wards at each 
identified facility completed the facility assessment form 
that collected information on availability of services and 
resources. For the main survey, 1- week training sessions 
were conducted with research assistants at the facility and 
country level on the objectives of the study, data collec-
tion procedures, practice sessions with the tools as well 
as highlighting ethical, safety and confidentiality consid-
erations. Techniques of information gathering on this 
sensitive and highly stigmatised topic using the medical 
records were also conducted during the training session 
and data collectors had access to facility coordinators and 
principal investigators for continuous support. Based on 
the eligibility criteria, research assistants at each facility 
reviewed and abstracted information from women’s 
medical records that included sociodemographic data, 
clinical information, obstetrics characteristics, signs and 
symptoms due to abortion- related complication, medical 
procedures, clinical outcomes and vital status at discharge 
to identify eligible women. Abstracted medical records 
data were transcribed into paper- based case report forms 
and entered into a web- based electronic data capture 
system developed by the Centro Rosario de Estudios Peri-
natales (Rosario, Argentina) for the study. Data entry 
was performed at the health facility or at a central level, 
dependent on logistics and available infrastructure. For 
the exit survey, data were collected on tablets using the 
audio computer- assisted self- interviewing (ACASI) system 
developed by Tufts University. The system allowed partic-
ipants to respond to the exit survey at a private location 
with a focus on maintaining participant confidentiality. 
Data collected in the exit survey consisted of abortion 
safety characteristics (method used, provider, setting) 
prior to coming to the facility, and women’s experience 
of abortion care related to effective communication, 
respect and dignity and emotional support during their 
time in the facility. The women who participated in the 
exit survey were compensated for their time by approx-
imately US$2 worth of mobile phone airtime. Data 
managers in Argentina continuously monitored the study 
data flow and data quality by use of validation procedures 
and progress reports for all countries. Data inconsisten-
cies were identified and corrected by contacting the study 
principal investigators as they emerged. These proce-
dures have been used in previous multicentre studies.25
Description of measures
Based on indicators present at time of hospital admission 
including clinical, laboratory and management- based 
markers, abortion- related complications were classified 
into five hierarchical and mutually exclusive categories 
based on severity: (1) deaths, (2) near miss, (3) potentially 
life- threatening complications, (4) moderate complications and 
(5) mild complications (figure 1).
Based on WHO criteria for near miss, women who died 
or identified as a near- miss case were classified as a severe 
maternal outcome.26 Women presenting with severe haem-
orrhage, severe systemic infection or suspected uterine 
perforation were classified based on WHO’s criteria for 
potentially life- threatening conditions.26 Moderate complications 
included bleeding, suspected intra- abdominal injury and 
infection. Mild complications included any abnormal signs 
from initial physical examination (vital signs, appear-
ance, mental status, abdominal examination, gynaecolog-
ical examination). Death was based on woman’s status at 
discharge. Online supplemental file 4 includes the iden-
tification criteria used for each severity category in detail 
and, online supplemental file 1 includes information on 
timing of abortion- related complications based on facility 
admission.
Gestational age at presentation was grouped as <13 
weeks, ≥13 weeks or undetermined weeks (online supple-
mental file 1). Clinical management of abortion- related 
complications was categorised as medically managed 
by uterotonics only, by uterine evacuation only or both 
methods. Uterotonics use was further divided into: miso-
prostol alone, oxytocin alone, ergometrine only and their 
combinations. Uterine evacuation was further examined 
by type of procedure: manual vacuum aspiration (MVA), 
dilation and curettage (D&C) and both.
Patient and public involvement
Development of the protocol used evidence from quali-
tative research exploring women’s experiences with abor-
tion care. The been published, the results will be dissemi-
nated for professional and non- professional audiences in 
participating countries.
Data analysis
Descriptive bivariate analysis was performed for national 
level and facility level characteristics (online supple-
mental file 1), as well as sociodemographic, obstetrics 
and clinical management characteristics by severity of 
abortion- related complications. The χ2 test was used to 
compare proportions of descriptive characteristics across 
severity categories. Severity of abortion- related compli-
cations is presented across countries as ratios calculated 
based on the prevalence of each category of complica-
tion per 1000 women with complications.
Descriptive analysis was also performed to evaluate the 
methods used, information received and help sought to 
end pregnancy for self- reported data collected in the exit 
interview via the ACASI platform. Experience of abor-
tion care during facility stay was assessed by comparing 
responses across severity of abortion- related complica-
tions using χ2 test.
Regression methods were used to evaluate women’s 
characteristics potentially associated with the outcome 
of abortion- related complication severity. Generalised 
linear models, adjusting for facility clustering effect 
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and differences across countries, were fitted to estimate 
the odds of severe maternal outcomes, potentially life- 
threatening complications and, moderate complications 
for women’s characteristics. The independent variables 
were categorical variables including sociodemographic 
characteristics (age, marital status, education, gainful 
occupation) and, obstetric characteristics (prior preg-
nancies, gestational age and expulsion of products of 
conception before arrival to the health facility).
Data analysis was conducted using SAS (V.9.4, Cary, 
North Carolina, USA).
RESULTS
We collected data on 15 671 women attending 210 facil-
ities in 11 sub- Saharan African countries (figure 1); 
124/210 (59·1%) of the facilities were secondary level 
facilities and most included received care in urban 
facilities (9,839, 72%). Details on facility characteristics 
included can be found in the online supplemental file 3.
A total of 73 women were excluded, of which 9 were 
excluded from these analyses as they did not have corre-
sponding facility records and 64 had ACASI data only 
without corresponding individual records. A further 
1815 (13·2%) women were excluded because they had 
complications related to molar and ectopic pregnancies 
(n=1782) or they did not have a final diagnosis (n=33). 
For 126 (0·9%) women, there was insufficient informa-
tion collected for severity to be determined and these 
women were excluded from the analyses. The final 
sample included 13 657 medical records and the analysis 
of these records focused on women with abortion- related 
complications.
Figure 1 Study flow diagram for severity of abortion- related complications. Severe maternal outcomes (SMOs) (n=323, 
2.3%). *Status at discharge. †WHO maternal near- miss criteria (organ dysfunction of either one or more of the following: 
cardiovascular, respiratory, renal, coagulation, hepatic, neurological or uterine dysfunction). ‡WHO potentially life- threatening 
complications (severe haemorrhage, severe systemic infection or suspected uterine perforation). §Moderate complications 
(heavy bleeding, suspected intra- abdominal injury or infection). ¶Mild complications based on abnormal physical examination 
findings on initial assessment (vital signs, appearance, mental status, abdominal examination, gynaecological examination).
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  Country- recognised medical abortion*,†
   None 2980 (21.8) 83 (25.7) 158 (16.5) 1919 (24.1) 820 (18.5)
   Misoprostol 4183 (30.6) 123 (38.1) 263 (27.5) 2098 (49.5) 1699 (38.4)
   Misoprostol- Mifepristone 6493 (47.6) 117 (36.2) 536 (56.0) 3936 (49.5) 1905 (43.1)
  National guidelines on abortions*,‡
   None 7435 (54.4) 186 (57.6) 480 (50.2) 4242 (53.3) 2527 (57.1)
   Postabortion care only 2429 (17.8) 33 (10.2) 236 (24.7) 1509 (18.9) 651 (14.7)
   Induced abortion and postabortion care 3793 (27.8) 104 (32.2) 241 (25.2) 2202 (27.7) 1246 (28.2)
Facility
  Facility type*
   Primary 1022 (8.4) 31 (9.9) 76 (8.7) 748 (10.4) 167 (4.4)
   Secondary 7505 (61.7) 139 (44.6) 421 (48.1) 4408 (61.4) 2537 (66.9)
   Tertiary 3630 (29.8) 142 (45.5) 378 (43.2) 2027 (28.2) 1083 (28.6)
  Location*
   Urban 9839 (72.0) 262 (81.1) 651 (68.0) 5717 (71.9) 3209 (72.5)
   Peri- urban 2080 (15.2) 32 (9.9) 105 (10.9) 1206 (15.2) 737 (16.6)
   Rural 1738 (12.7) 29 (8.9) 201 (21.0) 1030 (12.9) 478 (10.8)
Sociodemographic and obstetric
  Age (in years) 13 516
   ≤19 2173 (16.1) 58 (18.1) 157 (16.5) 1222 (15.5) 736 (16.9)
   20–29 6565 (48.6) 151 (47.0) 451 (47.3) 3866 (49.1) 2097 (48.1)
   ≥30 4778 (35.4) 112 (34.9) 345 (36.2) 2791 (35.4) 1530 (35.1)
  Marital status* 12 614
   Single 2852 (22.6) 104 (34.3) 246 (27.9) 1628 (22.2) 874 (21.4)
   Married/Cohabitating 9474 (69.4) 186 (61.6) 609 (69.1) 5548 (75.5) 3131 (76.7)
   Separated/Divorced/Widowed 288 (2.3) 12 (3.9) 27 (3.1) 174 (2.4) 75 (1.8)
  Education* 10 485
   No education 1791 (17.1) 41 (17.1) 125 (17.1) 1095 (18.3) 530 (15.0)
   Primary 3004 (28.7) 63 (26.3) 245 (33.6) 1640 (27.4) 1056 (29.9)
   Secondary or more 5690 (54.3) 136 (56.7) 360 (49.3) 3252 (54.3) 1942 (55.1)
  Gainful occupation* 11 708
   Yes 5276 (45.1) 119 (43.1) 337 (41.0) 3302 (48.4) 1518 (40.1)
  Previous pregnancies 13 264
   0 3584 (27.0) 79 (24.8) 231 (24.6) 2090 (26.9) 1184 (27.9)
   1 or more 9680 (72.9) 240 (75.2) 708 (75.4) 5678 (73.1) 2054 (72.1)
  Previous abortions 9434
   0 6050 (64.1) 154 (65.5) 462 (66.9) 3493 (63.1) 1941 (65.3)
   1 or more 3384 (35.9) 81 (34.5) 229 (33.1) 2041 (36.9) 1033 (34.7)
  Gestational age (in weeks)*
   <13 7214 (52.8) 118 (36.5) 378 (39.5) 4284 (53.9) 2434 (55.0)
   13–28 3998 (29.3) 112 (34.7) 372 (38.9) 2211 (27.8) 1303 (29.5)
Continued
6 Qureshi Z, et al. BMJ Global Health 2021;6:e003702. doi:10.1136/bmjgh-2020-003702
BMJ Global Health
Based on the inclusion criteria and available data on 
admission and discharge dates, 65.6% (8931/13614) of 
the women with abortion- related complications were 
eligible for ACASI exit interview. Of those, a total of 
3091/8931 (34·6%) women were recruited and partici-
pated in the ACASI exit interview.
Table 1 compares national, facility, demographic and 
obstetric characteristics of women, according to compli-
cation severity. Nearly half the sample, 6493 (47·6%) 
were from countries where both misoprostol and mife-
pristone were registered for medical abortion, and 7435 
women (54·4%) were from countries which do not have 
any national guidelines on abortion (induced abortion or 
postabortion care). Online supplemental file 2 describes 
the legal status of abortion in the study countries, with the 
majority of countries having a law that allows or permits 
abortion only on one or more legal grounds.27
Severity of abortion-related complications
Of all the women who had abortion- related complications 
(n=13 657), 264 (1·9%) women were classified as near- 
miss cases, 957 (7·0%) had potentially life- threatening 
complications, 7953 (58·2%) had moderate compli-
cations and 4424 (32·4%) women had mild complica-
tions. In addition, there were 59 (0·4%) deaths due to 
abortion- related complications. Abortion- related deaths 
and women with near- miss complications were grouped 
as severe maternal outcomes, representing a total of 
323 women (2·6%) (figure 1). Among women with near 
miss, the most common organ dysfunction identified was 
cardiovascular (165/264, 62·5%). Among potentially 
life- threatening, moderate and mild complications, the 
most commonly identified complications were severe 
haemorrhage (703/957, 73·2%), heavy bright bleeding 
(7656/7953, 96·3%) and vaginal bleeding (3470/4424, 
78·4%) (online supplemental file 4).
Among women presenting to facilities with an abortion- 
related complication (n=13 657), they were between 
the ages of 20 and 29 years, and most were married or 
cohabitating (77·4%) and reported secondary educa-
tion or above (54·3%). Less than half of the women 
were gainfully employed. According to their obstetric 
history, most women had a previous pregnancy (91·5%) 
and many (64·1%) did not have any previous abortions. 
Significant differences were observed across severity cate-
gories for marital status, education, gainful occupation 
and timing of expulsion of products of conception.
Figure 2 describes the severity of complications across 
countries per 1000 women with complications. Severe 
maternal outcomes ranged from 5 per 1000 women in 
Niger to 48 per 1000 women in Nigeria. Potentially life- 
threatening complications ranged from 14 per 1000 
women in Niger to 105 per 1000 women in Uganda. 
Moderate complications ranged from 395 per 1000 
women in Malawi to 795 per 1000 women in Benin, and 
the mild complications ranged from 91 per 1000 women 
in Benin to 536 per 1000 women in Niger.
Table 2 presents generalised linear models evaluating 
women’s characteristics associated with severe maternal 
outcomes, potentially life- threatening and moderate 
abortion- related complications compared with mild 
complications, adjusting for country, age, education, 
occupation, prior pregnancy and gestational age and 
timing of expulsion of products of conception. In the 
adjusted model, being single (adjusted OR (aOR): 3·4 
(95% CI 2·2 to 5·3)), having prior pregnancies (aOR: 2·1 
(95% CI 1·3 to 3·5)) and presenting at later gestational 
ages (≥13 weeks) (aOR: 3·5 (95% CI 2·3 to 5·4)) were 
positively associated with experiencing severe maternal 
outcomes compared with women with mild complica-
tions. Furthermore, our model shows that women who 
had expulsion of products of conception prior to arrival 
to the health facility were twice (aOR: 2·3 (95% CI 1·6 to 
3·4)) as likely to experience severe maternal outcomes.
When women with potentially life- threatening 
complications were compared with mild complications 
(adjusting for country, age, education, occupation, prior 
pregnancy and gestational age and timing of expulsion 
of products of conception), similar pattern to severe 
maternal outcomes were observed (table 2). In the 















   Undetermined 2445 (17.9) 93 (28.8) 207 (21.6) 1458 (18.3) 687 (15.5)
  Expulsion of products of conception before 
arrival to facility*
13 616
   Yes 5916 (43.5) 177 (55.1) 511 (53.7) 3299 (41.6) 1929 (43.7)
*P<0.0001.
†None (Niger, Burkina Faso, Chad); misoprostol (Benin, Ghana, Kenya, Uganda); misoprostol- mifepristone (DRC, Malawi, Mozambique, 
Nigeria).
‡None (Burkina Faso, DRC, Chad, Malawi, Niger, Uganda); postabortion care (Kenya only); induced abortion and postabortion care (Benin, 
Ghana, Mozambique, Nigeria).
DRC, Democratic Republic of the Congo.
Table 1 Continued
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1·8)), having prior pregnancies (aOR: 1·2 (95% CI 1·0 
to 1·5)), presenting at later gestational ages (≥13 weeks) 
(aOR: 1·7 (95% CI 1·3 to 2·2)) and expulsion of products 
of conception prior to arrival to the health facility (aOR: 
1·8 (95% CI 1·4 to 2·2)) are positively associated with 
experiencing potentially life- threatening complications. 
Women with no or primary education were more likely 
to experience potentially life- threatening complications: 
1·5 (95% CI 1·2 to 1·9), 1·4 (95% CI 1·2 to 1·7). Finally, 
women with moderate complications had no significant 
associations, except slightly elevated odds with primary 
education 1·1 (95% CI 1·0 to 1·3), compared with mild 
complications.
Management of abortion-related complications
As shown in table 3, approximately 50% of the women 
received both uterotonics and underwent uterine evac-
uation for management of abortion- related complica-
tions across all severity categories. For other manage-
ment types, 16·7% of women received uterotonics only 
and 27·6% of women underwent uterine evacuation 
only. Across severity categories, for mild complications, 
uterine evacuation was performed more commonly 
(35·6%) than for the other groups. Women with poten-
tially life- threatening (56·7%) or moderate complica-
tions (52·5%) more commonly received both uterotonics 
and uterine evacuation compared with women with mild 
complications (44·2%) and severe maternal outcomes 
(35·3%).
Table 4 details the type of management for our study 
sample. Overall, 66·4% of women received uterotonics, 
and among those the most commonly used was oxytocin 
(50·9%), followed by misoprostol (22·7%). Uterine 
evacuation was performed in 77·3% women, the most 
common method used was MVA (in 76·9% women), and 
its use was most frequent in the moderate cases (79·3%). 
Following MVA, D&C was used among 20·1% of women. 
8·1% of the women received blood products and their 
use was mostly among the severe maternal outcomes 
(55·4%) and potentially life- threatening complica-
tions (48·2%). A total of 121 women underwent major 
surgeries. The most common were exploratory lapa-
rotomy, (76%) and hysterectomy (21·5%). Almost 9 out 
of 10 women received antibiotics for prophylaxis of treat-
ment. Among the small number of women (77, 0·6%) 
who were admitted to intensive care unit, the majority 
were those with severe maternal outcomes.
Women’s self-reported experiences of abortion care via ACASI 
exit survey
Distribution of sociodemographic and obstetric charac-
teristics of the women who participated in the ACASI exit 
interview were not significantly different from the overall 
study population (except for gestational age) (online 
supplemental file 5). Of the 3091 women who undertook 
ACASI exit interview, only 602 women (19·5%) reported 
having used one method or more to end their preg-
nancy. The most commonly reported methods to end the 
pregnancy were: misoprostol (54·3%), other medicines 
either orally or vaginally (40·5%) and procedures that 
cleared out contents from the uterus (38·7%). Further-
more, 18·7% reported using of herbs, antimalarial drugs, 
bleach, gasoline and detergents and 14·3% reported 
using traditional abdominal massage.
Figure 2 The severity of abortion- related complications 
across countries per 1000 women . A: Severe maternal 
outcomes; B: Potentially- life threatening complications; C: 
Moderate complications; D: Mild complications. Figures 
are drawn to scale for each severity category. BEN, Benin; 
BFA, Burkina Faso; TCD, Chad; DRC, Democratic Republic 
of Congo; GHA, Ghana; KEN, Kenya; MWI, Malawi; MOZ, 
Mozambique; NER, Niger; NGA, Nigeria; UGA, Uganda
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Of the 602 women who reported induced abortion, 
241 (39·9%) reported that they did not receive any 
information about the method used to end pregnancy. 
For the rest, the most commonly reported sources of 
information were friends (33·4%), husband /partner/
boyfriend (28·9%), followed by healthcare providers 
(25·1% medical doctor, 24·5% pharmacist, 23·4% nurse/
midwife). More than 1 in 10 women reported getting 
information through internet or social media, whereas 
only 6·8% reported radio or TV as a source of information 
(figure 3). In terms of receiving assistance from someone 
to end their pregnancy, 261 (42·7%) of the women did 
not get any help. The most commonly reported assistance 
was from healthcare providers (23·4% medical doctors, 
21·6% nurse/midwifes, 16·8% pharmacist). Of note, 
more than one in five women reported being assisted by 
a friend (figure 3).
Table 5 presents experience of abortion care during 
facility stay as reported by women. Overall, 19·1% of 
the women stated that they were not given explanations 
regarding their care and treatment. One out of three 
women reported that they were not able to ask questions 
during their examination and treatment. Overall, 18·5% 
of women felt their choices and preferences were not 
Table 2 Determinants of increased risk of abortion- related complication severity compared with mild complications observed 
among women who sought care at a facility
    SMOs vs mild PLTC vs mild Moderate vs mild
  aOR 95% CI aOR 95% CI aOR 95% CI
Age (in years) ≤19 1.5 (0.8 to 2.7) 1.0 (0.8 to 1.3) 1.1 (0.9 to 1.3)
20–29 0.9 (0.7 to 1.2) 0.9 (0.8 to 1.1) 1.1 (0.9 to 1.2)
≥30 Reference Reference Reference Reference Reference Reference
Marital status Single 3.4† (2.2 to 5.3) 1.5† (1.2 to 1.8) 1.0 (0.9 to 1.1)
Other than single Reference Reference Reference Reference Reference Reference
Education No education 0.7 (0.4 to 1.3) 1.5* (1.2 to 1.9) 1.0 (0.8 to 1.2)
Primary 1.3 (0.9 to 1.9) 1.4† (1.2 to 1.7) 1.1* (1.0 to 1.3)
Secondary or more Reference Reference Reference Reference Reference Reference
Gainful 
occupation
No 1.2 (0.8 to 1.6) 1.1 (0.9 to 1.3) 0.9 (0.9 to 1.1)
Yes Reference Reference Reference Reference Reference Reference
Prior pregnancies 1 or more 2.1* (1.3 to 3.5) 1.2* (1.0 to 1.5) 1.1 (0.9 to 1.2)
0 Reference Reference Reference Reference Reference Reference
Gestational age 
(in weeks)
13–28 3.5† (2.3 to 5.4) 1.7* (1.3 to 2.2) 1.1 (0.9 to 1.4)
Undetermined 2.3† (1.6 to 3.2) 1.4* (1.2 to 1.6) 1.1 (0.9 to 1.2)





Yes 2.3† (1.6 to 3.4) 1.8† (1.4 to 2.2) 1.0 (0.9 to 1.2)
No Reference Reference Reference Reference Reference Reference
*P<0.05.
†P<0.0001.
aOR, adjusted OR; PLTC, potentially life- threatening complication; SMO, severe maternal outcome.
Table 3 Uterotonics and uterine evacuation for management of abortion- related complications by severity*













Uterotonics 2280 (16.7) 62 (19.2) 120 (12.5) 1493 (18.8) 605 (13.7) <0.0001
Uterine evacuation 3765 (27.6) 74 (22.9) 212 (22.2) 1904 (23.9) 1575 (35.6)
Both uterotonics and 
uterine evacuation
6790 (49.7) 114 (35.3) 543 (56.7) 4177 (52.5) 1956 (44.2)
Other 634 (4.6) 68 (21.1) 77 (8.1) 282 (3.6) 207 (4.7)
None 188 (1.4) 5 (1.6) 5 (0.52) 97 (1.2) 81 (1.8)
*Mutually exclusive.
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followed during hospital stay and this differed signifi-
cantly across severity categories. Women who reported not 
being spoken to nicely during their stay ranged between 
6·9% among women with potentially life- threatening 
complications and 9·8% among women with moderate 
complications; 13·2% of women reported not having 
received pain medications during their stay ranging from 
9·9% among women with severe complications to 14·6% 
among women with moderate complications.
DISCUSSION
Our study quantified the health burden experienced by 
women presenting with abortion- related complications in 
11 sub- Saharan African countries. We used a gradient to 
examine and report on the severity of and management 
of abortion- related complications across 13 657 women, 
210 health facilities and subsample of women- reported 
experiences. Of all women with abortion- related compli-
cations, approximately 2.3% were identified as severe 
maternal outcomes, 7.0% potentially life- threatening 
complications, 58% moderate and 32% mild complica-
tions. The proportion of women presenting with severe 
maternal outcomes and potentially life- threatening 
complications indicates that unsafe abortion continues 
to pose a major public health challenge in Africa. The 
prevalence of these severe complications varies across 
countries, compared with other findings, illustrating the 
issues with comparability due to lack of a standardised 
approach in measurement of abortion- related compli-
cations. Globally, at least 9% of abortion- related compli-
cations in health facilities were identified as a near- miss 
event,13 while studies from Africa report varying preva-
lence of severe abortion- related complications. These 
studies have used different criteria, ranging from Rees 
Table 4 Types of management by severity of abortion- related complications†
  Severity of abortion- related complications












Uterotonics* 9071 (66.4) 176 (54.5) 663 (69.3) 5670 (71.3) 2562 (57.9)
Misoprostol only 2055 (22.7) 33 (18.8) 117 (17.7) 1293 (22.8) 612 (23.9)
Misoprostol and ergometrine 154 (1.7) 0 6 (0.9) 110 (1.9) 38 (1.5)
Oxytocin only 4622 (50.9) 94 (53.4) 353 (53.2) 2749 (48.5) 1426 (55.7)
Oxytocin and ergometrine 463 (5.1) 3 (1.7) 40 (6.0) 392 (6.9) 28 (1.1)
Ergometrine 346 (3.8) 7 (3.9) 26 (3.9) 192 (3.4) 121 (4.7)
Misoprostol and oxytocin 1102 (12.2) 30 (17.1) 98 (14.8) 673 (11.9) 301 (11.8)
Misoprostol, oxytocin and ergometrine 291 (3.2) 9 (5.1) 22 (3.3) 230 (4.1) 30 (1.2)
Other 38 (0.4) 0 1 (0.2) 31 (0.6) 6 (0.2)
Uterine evacuation* 10 555 (77.3) 188 (58.2) 755 (78.9) 6081 (76.5) 3531 (79.9)
Manual vacuum aspiration (MVA) 8124 (76.9) 136 (72.3) 544 (72.1) 4823 (79.3) 2621 (74.2)
Dilation and curettage (D&C) Only 2125 (20.1) 48 (25.5) 185 (24.5) 1065 (17.5) 827 (23.4)
Both MVA and D&C 56 (0.5) 1 (0.5) 8 (1.1) 36 (0.6) 11 (0.3)
Other 250 (2.4) 3 (1.6) 18 (2.4) 157 (2.6) 72 (2.0)
Blood transfusion* 1129 (8.3) 179 (55.4) 461 (48.2) 368 (4.6) 121 (2.7)
1 unit 570 (51.6) 65 (36.9) 218 (47.6) 214 (60.8) 73 (61.9)
2 units 365 (33.1) 62 (35.2) 171 (37.3) 96 (27.3) 36 (30.5)
3 units or more 169 (15.3) 49 (27.8) 69 (15.1) 42 (11.9) 9 (7.6)
Surgical procedures* 121 (0.88) 40 (12.4) 41 (4.3) 19 (0.24) 21 (0.47)
Laparoscopy 3 (2.5) 0 0 3 (15.8) 0
Exploratory laparotomy 92 (76.0) 24 (60.0) 40 (97.6) 14 (73.7) 14 (66.7)
Hysterectomy 26 (21.5) 16 (40.0) 1 (2.4) 2 (10.5) 7 (33.3)
Antibiotics received for prophylaxis or 
treatment*
12 215 (89.5) 6516 (90.3) 3576 (89.4) 7205 (90.6) 3794 (85.8)
Admission to intensive care unit* 77 (0.6) 38 (11.8) 20 (2.1) 10 (0.1) 9 (0.2)
*P<0.0001.
†Not mutually exclusive.
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et al28 to expanded WHO near- miss criteria,29 to define 
and measure complication severity, leading to different 
estimations as seen from various studies in DRC (16%), 
Kenya (37%), Malawi (21%), Zambia (16%) and 
Zimbabwe (19%).8 9 11 30 31 Our results underline the 
importance of using standardised definitions including 
the application of WHO’s near- miss criteria29 to ensure 
comparability when quantifying the burden of abortion- 
related complications as well as measuring the progress 
globally and in the context of Africa.12 13
Our results show that 9 out of 10 women who seek care 
in the facilities have moderate or mild complications 
(most commonly with some form of vaginal bleeding), 
which may reflect the changing tide of abortion due to 
medical abortion. After medical abortion use, WHO 
recommendations on medical abortion highlights that 
vaginal bleeding for 2 weeks is normal and serious side 
effects including adverse events are rarely reported with 
the appropriate medical abortion regimen.6 We were 
not able to discern whether vaginal bleeding was due to 
medical abortion use prior to seeking care in facilities. A 
plausible explanation is that women presenting with mild 
complications may have been experiencing this common 
side effect of medical abortion use which highlights the 
importance of access to quality information and services 
regarding medical abortion.
Severe abortion- related complications were associated 
with being single, having a prior pregnancy and late 
gestational age (≥13 weeks), with over a twofold increase 
in odds among severe maternal outcomes. These findings 
are consistent with other studies that found increased 
likelihood of severe abortion- related complications due 
to similar characteristics.8 11 31 32 Abortion remains a stig-
matised issue in Africa creating further inequities and 
vulnerabilities for women based on their socioeconomic 
characteristics, such as marital status, contributing to 
severe complications.10 Severe abortion- related compli-
cations were also associated with expulsion of products of 
conception (POC) prior to arrival to the facility. This may 
be attributable to a number of possible gaps in the infor-
mation channels regarding the recommended medical 
abortion dosage, on when to seek postabortion care, side 
effects and symptoms of possible complications.10 33–35 
Women might also not be aware of the services available, 
may fear stigma and mistreatment and use methods which 
are considered unsafe. According to a systematic review, 
awareness and knowledge of the abortion laws and policy 
environment among women was limited, even in coun-
tries where the laws were liberal, hindering women from 
accessing available services.36
In terms of management of abortion- related compli-
cations at the health facility, approximately half of the 
abortion- related complications were treated with both 
uterotonics and uterine evacuation. The use of both 
uterotonic and uterine evacuation may be a reflection 
of overmedicalization due to possible provider prefer-
ence and practice rather than evidence- based recom-
mendations.37 This is particularly important among mild 
complications presenting with vaginal bleeding that 
may have been due to medical abortion use prior to the 
facility. The management of abortion- related complica-
tions using safe and low- cost technologies, such as MVA, 
which is the recommended method of uterine evacua-
tion regardless of severity,3 is on the rise across countries 
in our study; however, the use of non- recommended and 
unsafe methods such as D&C still persists. This may be 
due to lack of resources (eg, equipment and supplies)38 
and/or training, which might lead providers to use 
Figure 3 Self- reported sources of information and help used to end pregnancy (n=602). *Response option only included for 
information question. †Response option only included for help question.
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outdated methods like D&C.10 12 39 Furthermore, half of 
our cases received oxytocin as the most common method 
of uterotonics, rather than misoprostol, which is recom-
mended to manage abortion- related complications.6 40 
The less frequent use of misoprostol may be due to lack 
of availability, familiarity, training and guidelines as well 
as providers’ perceptions on misoprostol being a less 
effective and safe method of postabortion care.12 40 The 
inequities in the provision of good quality care highlight 
the need to strengthen the adoption and implementa-
tion of evidence- based recommendations for the provi-
sion of postabortion care.4 41
Of the participating women in the ACASI exit survey, 
one in two reported induced abortion with the most 
commonly used method being misoprostol, whereas one 
in five still reported using dangerous methods such as 
antimalarial drugs, or insertion of something into the 
vagina. This supports the trends observed that medical 
abortion is becoming more commonly used among 
women and possibly contributing to the reduction in 
the burden of severe complications.1 Furthermore, our 
results indicate that a small but significant proportion 
of women accessed information through social media 
and internet. This suggests that these channels may be 
used for informing women about safe abortion options 
and postabortion care (in areas where internet access is 
available) paving the way for telemedicine to be adopted 
given the evidence that it is becoming more acceptable 
to women and providers.42 Reducing the burden of both 
severe and mild complications among women can be 
improved through implementation of evidence- based 
practices which include provision of accurate informa-
tion and resources for women seeking medical abortion 
outside of healthcare facilities.3 33 34 43 These approaches 
might also be applicable to better inform women about 
what to expect after medical abortion and when to seek 
care from facilities, reducing the burden on women and 
health systems alike.
For women’s experiences of postabortion care, among 
those participating in the exit survey, one in five women 
felt that their choices and preferences were not followed 
during care and the same proportion did not receive 
explanations regarding their care. Evidence shows that 
mistreatment during childbirth in the facility may be a 
Table 5 Self- reported experience of abortion care during facility stay















  N (%) N (%) N (%) N (%)
Explanations regarding care and treatment (n=2950)
  No 562 (19.1) 25 (27.5) 63 (20.7) 333 (18.9) 141 (17.7)
  Able to ask questions during the examination and 
treatment (n=2950)
  No 1009 (34.2) 31 (34.1) 115 (37.8) 610 (34.7) 253 (31.8)
Feel healthcare provider informed you about decisions taken for care (n=2944)
  No 639 (21.7) 22 (24.2) 73 (24.0) 385 (21.9) 159 (20.0)
Encountered anxiety or stress during hospital stay (n=2942)
  Yes 1587 (53.9) 53 (58.2) 163 (53.9) 949 (54.1) 422 (53.1)
  If yes to above (n=1585), not able to tell healthcare 
provider who helped you that you were feeling anxious 
or stress
679 (42.8) 20 (37.7) 63 (38.7) 422 (44.6) 174 (41.2)
  If yes to above (n=906), not offered additional support 
when you told the healthcare provider about feeling the 
anxiety or stress
102 (11.3) 2 (6.1) 6 (6.0) 69 (13.1) 25 (10.1)
Feel choices and preferences were followed during hospital stay* (n=2935)
  No 542 (18.5) 17 (18.7) 48 (16.0) 352 (20.1) 125 (15.7)
Spoken to nicely (n=2940)
  No 257 (8.7) 7 (7.7) 21 (6.9) 172 (9.8) 57 (7.2)
Receive pain medications during hospital stay (n=2940)
  No 389 (13.2) 8 (8.8) 31 (10.3) 255 (14.6) 95 (11.9)
  If yes (n=2551), pain medications did not help ease pain 144 (5.6) 5 (6.0) 9 (3.3) 83 (5.5) 47 (6.7)
*P<0.05.
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significant barrier to women’s decision to seek care.44 
Furthermore, provider perceptions on abortion care and 
workload can negatively impact provider- patient interac-
tion, timeliness and quality of care.12 Globally, there is 
growing interest in measuring person- centred reproduc-
tive healthcare including abortion care, contraception 
and maternity care.38 45–47 While the evidence around 
measuring women’s experiences seeking abortion- 
related care, in particular, is limited, research efforts are 
increasing to support the development of measurement 
tools.38
Strengths and limitations
We sought to use a standardised approach to identify 
abortion- related complications across 210 facilities in 11 
countries. The large sample size and number of partic-
ipating facilities enables generalisability of results to 
facilities with similar outcomes and geographical areas 
similar to those included in our study, and other sub- 
Saharan African countries (lusophone, francophone, 
anglophone). Our results are not representative of the 
population and despite the implementation of standard-
ised definitions for abortion- related complications, a few 
data collection issues linked to the quality of the medical 
records (eg, poor record keeping, especially on abortion) 
may have led to underestimation and/or misclassification 
of severity across countries. Furthermore, depending on 
the countries and the context, including the abortion 
rate, the number percentage of women experiencing a 
complication after abortion and further seeking care at 
the facilities might vary. Due to the sensitive nature of the 
topic in all the study countries, we did not differentiate 
between induced and spontaneous abortion during data 
collection, and it should be noted that induced abortion- 
related complications may be more severe compared 
with spontaneous abortions.13 Our study is based on a 
cross- sectional survey across facilities and limited to the 
women who present at these facilities for abortion- related 
complications. The study also incorporated a confiden-
tial self- reported exit interview component to measure 
women’s experiences of abortion care (prior to coming 
and during their facility stay) using the ACASI software. 
ACASI was used given that it is well- suited for collecting 
data on sensitive data; however, women may have still 
under- reported induced abortion.
CONCLUSION
Unsafe abortion remains a critical public health issue 
in sub- Saharan African countries, causing significant 
morbidity for women and burden on health systems. 
Based on our results, future areas of work include using 
the standardised approach to quantify abortion- related 
complications in health facilities, implementing clin-
ical management practices in line with evidence- based 
recommendations and conducting further research to 
develop measurement tools to report women’s expe-
riences of abortion care. Delays in seeking care for 
abortion- related complications increases the risk of 
severe morbidity, therefore there is a need to strengthen 
provision of accurate information and services to reduce 
such delays. It is vital for countries to implement context- 
specific programmes to increase access to and quality of 
safe abortion and contraception services.
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